Please login to the form below

Not currently logged in

licence deal

This page shows the latest licence deal news and features for those working in and with pharma, biotech and healthcare.

US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

The three companies started negotiations with a view agreeing a licence deal to settle the disputes, but that effort was abandoned without agreement.

Latest news

  • Boehringer bolsters NASH pipeline with $870m Yuhan deal Boehringer bolsters NASH pipeline with $870m Yuhan deal

    Strengthens existing relationship. Boehringer Ingelheim has added to its non-alcoholic steatohepatitis (NASH) pipeline once again via a licence deal with South Korean biotech Yuhan. ... Yuhan said that the combined molecule will be developed using

  • Biogen picks up another drug from wide-ranging Ionis alliance Biogen picks up another drug from wide-ranging Ionis alliance

    The drug isn’t from that extension, rather it stems from an earlier licence deal between the companies dating back to 2013. ... Under the terms of the deal, Ionis receives $35m upfront and is eligible for another $55m in milestones, plus royalties up

  • Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal

    Japanese pharma company Otsuka has licensed an Alzheimer's disease drug candidate from Lundbeck in a deal that expands an ongoing collaboration between the two companies to include a third drug.

  • AZ moves to strengthen diabetes, cancer pipelines

    Tokyo-based Prosidion has already advanced the lead compound in the licence deal - called PSN821 - into phase II testing, while AstraZeneca has also take an option for a follow-up (PSN842) ... AstraZeneca has paid Prosidion an undisclosed option fee

  • Eastern Europe targeted

    The largest licence deal in May, financially, was that reported between Glenmark and Sanofi. ... COPD). As Almirall will be developing its own brand, this deal is more like a licence and as such commanded an undisclosed upfront fee.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... The deal also includes a licence to

  • Deal Watch October 2016 Deal Watch October 2016

    Astellas has structured its deal almost like a licence with one third of the consideration ($462m) upfront and the remainder in “further contingent milestones” (milestones and possibly royalties) as the product ... The licence deal obtained by Summit

  • Deal Watch May 2016 Deal Watch May 2016

    Building on its 2014 deal with MacroGenics, J&J entered into a licence and collaboration agreement for MGD015 for B-cell malignancies with an upfront fee of $75m and $665m in ... Another deal which has taken a hybrid licence / acquisition format is that

  • Deal Watch January 2016 Deal Watch January 2016

    The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected peak sales in the range of $0.6bn to $1.0bn (the first nine ... Licensor/Acquired Acquiror/Partner. Deal Type. Comments. Hline $m. Baxalta/

  • Pharma deals in July 2015 Pharma deals in July 2015

    Biogen also broke the $1bn headline in a licence and collaboration deal with AGTC for gene based therapies to treat ophthalmic diseases. ... A strange coincidence! Licensor/Licensee Acquired / Acquirer. Deal type. Product/Technology. Headline $m.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...